Nanjing Hongyun Biotechnology

Hongyun Pharma is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation small molecule precision medicines for oncology. The company utilizes a proprietary structure-based drug discovery platform that integrates computational chemistry, molecular dynamics, and structural biology to target specific genetic drivers of cancer. Their lead candidate, H002, is a potent fourth-generation EGFR inhibitor designed to address the C797S resistance mutation in patients with non-small cell lung cancer. Beyond EGFR, the company is advancing a robust pipeline of inhibitors targeting KRAS and BRAF mutations. With operations in both China and the United States, Hongyun Pharma aims to deliver innovative therapies to patients globally.